Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2023

Commission File Number: 001-38547

 

Autolus Therapeutics plc

(Translation of registrant’s name into English)

 

The MediaWorks

191 Wood Lane

London W12 7FP

United Kingdom

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x  Form 20-F    ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

INCORPORATION BY REFERENCE

This Report on Form 6-K (the “Report”), excluding Exhibit 99.1 to this Report, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333-258556), Form F-3 (File No. 333-264304), Form F-3 (File No. 333-264650) and Form S-8 (File No. 333-226457) of Autolus Therapeutics plc (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

---

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On January 20, 2023, John H. Johnson, the chair of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of his intention not to stand for re-election at the Company’s 2023 Annual General Meeting of Shareholders. Mr. Johnson has indicated that this decision was not the result of any disagreement with the Company’s management or Board.

On January 20, 2023, Dr. Jay T. Backstrom, a non-executive director of the Company, notified the Company of his intention to resign from the Board effective February 28, 2023. Dr. Backstrom has indicated that this decision was not the result of any disagreement with the Company’s management or Board.

On January 20, 2023, the Company issued a press release announcing the aforementioned changes to the Board, which is furnished as Exhibit 99.1 to this Report

EXHIBIT INDEX

 

Exhibit No.						Description
99.1						Press release dated January 20, 2023

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Autolus Therapeutics plc

Date:

January 23, 2023

By:

/s/ Christian Itin

Name

Christian Itin, Ph.D.

Title:

Chief Executive Officer